Project Grant R43CA291515
Award Date
8/15/24
Completion Date
7/31/25
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Keliomics, Inc. (XA5ZBZCGLUV5)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
The U.S. National Cancer Institute (NCI) awarded a $450,000 Project Grant under the CFDA 93.396 Cancer Biology Research program to The Research Foundation for the State University of New York, doing business as Stony Brook University. The project, titled "Topological Methods for Breast Tissue Quantification," aims to develop advanced algorithms and analytical techniques using topological data analysis (TDA) to extract and interpret fine-grained structural information from breast...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a $644,804 research project titled "Advancing Breast Cancer Risk Assessment for Black Women." The project aims to develop and validate a novel deep learning-based breast cancer risk assessment tool focused on Black women, leveraging digital breast tomosynthesis (DBT) imaging data. Key objectives include: Developing a DBT-driven...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Promilead, LLC to evaluate a small-molecule compound, USCYL01, as a potential therapy to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) assess the toxicity and pharmacokinetic properties of USCYL01 in vitro and in vivo, and 2) test USCYL01 as an adjunct to ICI plus...
This Project Grant award of $399,444.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cancure LLC, a woman-owned small business, aims to screen a panel of fusion proteins composed of a peptide and a binding agent. The goal is to identify the best candidate to advance or make a go/no-go decision regarding the fusion product, while also conducting pilot de-risking biochemical/biophysical characterizations. This research seeks to develop a novel agent...
The National Cancer Institute (NCI) awarded a $585,931 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The grant, effective February 3, 2025 through January 31, 2030, will support a research project titled "Single-Cell Congruence Evaluation and Selection of Cancer Models Towards Precision Medicine." The project aims to: 1) Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer,...
This $369,868 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the functional role of mitochondrial transfer from nerves to breast cancer cells, and how this process impacts cancer metastasis and the generation of cancer stem cells. The project aims to use innovative lineage-tracing techniques to quantify the contribution of nerve-to-cancer mitochondrial transfer to the breast cancer metastasis cascade, and evaluate...